Denileukin diftitox
Lymphir · Immunotoxin (IL-2–diphtheria)
Capillary-leak syndrome → prerenal AKI.
Bispecific T-cell engager (gp100×CD3 ImmTAC)
Kimmtrak · Tebe
Bispecific T-cell engager (gp100×CD3 ImmTAC) · approved 2022 · 4 citations
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
A gp100×CD3 ImmTAC whose renal risk is CRS-driven hypotension early in treatment — prerenal AKI.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
Cytokine release syndrome is very common early in treatment and, with the associated hypotension, is the principal mechanism of acute kidney injury; severe sepsis-like CRS with hypotension has been reported. The pivotal phase 3 trial established CRS, hypotension and rash as defining toxicities, mitigated by weekly step-up dosing. A dedicated tebentafusp renal/AKI study does not exist; renal injury is inferred from the CRS literature.Source: Nathan et al., NEJM 2021 (pivotal phase 3); Geidel et al., JEADV 2023 (sepsis-like CRS case)
Early — first 1–3 weekly doses, coinciding with peak CRS.
Distilled from: “Early — first 1–3 weekly doses, coinciding with peak CRS.”
This agent's defining kidney lesion — its #1 signature. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.
Bispecific gp100 peptide-HLA-directed T-cell engager (ImmTAC) that fuses an affinity-enhanced T-cell receptor recognizing a gp100 peptide presented on HLA-A*02:01 to an anti-CD3 effector domain, redirecting polyclonal T cells to kill gp100+ uveal melanoma cells. Approved for HLA-A*02:01-positive unresectable or metastatic uveal melanoma.
Vasculature / Endothelium
Glomerular & peritubular capillaries
Class-level context for the major non-renal toxicities of the Bispecific T-cell engager (gp100×CD3 ImmTAC) class.
Immune / Infusion
CRS, infusion reactions, irAEs, anaphylaxis
Neurologic
Neuropathy, encephalopathy, ICANS, PRES
Hematologic
Cytopenias, thrombosis, TMA
4 primary references — trials, cohorts, mechanism, and reviews. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Quoted verbatim from this agent's current FDA label (Aug 2026) — not paraphrased or interpreted. Full label on DailyMed .
Boxed warning
BOXED WARNING: CYTOKINE RELEASE SYNDROME Cytokine Release Syndrome (CRS), which may be serious or life-threatening, occurred in patients receiving KIMMTRAK. Monitor for at least 16 hours following first three infusions and then as clinically indicated [(see Dosage and Administration (2.2) , see Warnings and Precautions (5.1) ] . WARNING: CYTOKINE RELEASE SYNDROME Cytokine Release Syndrome (CRS), which may be serious or life-threatening, occurred in patients receiving KIMMTRAK. Monitor for at least 16 hours following first three infusions and then as clinically indicated ( 2.2 , 5.1 ).
Kidney rows of the label's dosage tables
From the KIMMTRAK label (Aug 2026) · DailyMed
No row of this label's 3 dosage tables names a kidney term together with a withhold, reduce, resume or discontinue instruction. That covers those four instructions in the tables only: a table can still set a starting dose by creatinine clearance, and the prose can give other kidney instructions. The full label on DailyMed has both.
Everything below is FAERS — adverse events someone chose to report, about 602 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Reported with a death outcome
107 of 602 reports
Reported with hospitalization
201 of 602 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Tebentafusp sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Lymphir · Immunotoxin (IL-2–diphtheria)
Capillary-leak syndrome → prerenal AKI.
Vyloy · Anti-Claudin-18.2 monoclonal antibody
2024 gastric mAb; severe on-target nausea/vomiting → volume-depletion prerenal AKI.
Lonsurf · Oral fluoropyrimidine + TP inhibitor
Tipiracil is renally cleared; reduced GFR raises exposure and early severe neutropenia; dose-reduce in renal impairment.
Orserdu · Oral selective estrogen-receptor degrader (SERD)
2023 oral SERD; nausea-dominant, minimal intrinsic nephrotoxicity.
Tivdak · Antibody-drug conjugate (tissue factor/MMAE)
Ocular/bleeding toxicity dominates; renal involvement essentially unreported.
Ojemda · Type II pan-RAF (BRAF) inhibitor
2024 pediatric glioma RAF inhibitor; creatinine rise.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.